48. Beyond accelerated drug development: building successful partnerships and platforms as a critical path to TB drug regimens and PreDiCT-TB

Saturday, 05 December 2015, 15:30 - 17:00
Room MR 2.61-2.63

Type of session: Symposium
Track: TB other

Description: The Critical Path to TB Drug Regimens (CPTR) and PreDiCT-TB aim to accelerate TB drug development and build short-duration treatment regimens and rapid diagnostics. CPTR successfully had the hollow-fiber model of TB qualified by the European Medicines Agency as a drug development tool for TB, and is leading regulatory work on liquid cultures and modelling and simulation tools. PreDiCT–TB systematically evaluates pre-clinical models in TB and databases of individual patient data from TB clinical trials. This symposium will share experiences with partners and discuss advances in pre-clinical models of TB translational platforms and clinical trial design.

Target audience:
1. TB drug developers, researchers
2. Clinical trialists, patients, advocates
3. Policy experts

Objectives:
1. Discuss building a data-sharing public-private partnership platform across disciplines in TB drug development
2. Analyse current knowledge gaps in translational TB research and lessons learned from recent trials
3. Outline a new paradigm of partnership for development of more informed and effective translational models
4. Consider remapping of data from other clinical trials for other purposes
5. Discuss the way forward

Keywords: Preclinical models, rapid diagnostics, modeling and simulation, private-public consortia

Coordinator(s): Marco Schito (USA)
Chair(s): Debra Hanna (USA)

Presentations:

15:30 - 15:40 Lessons from the qualification of the pre-clinical hollow fiber system model of tuberculosis (HFS-TB)
Jotam Pasipanodya (USA)

15:45 - 15:55 Collaborative approaches to defining contribution of animal models
Henry Pertinez (UK)

16:00 - 16:10 Learning from clinical trial data
Laura Bonnett (UK)

16:15 - 16:25 Improving TB clinical trial design through modeling and simulation
Klaus Romero (USA)

16:30 - 16:40 Translational modelling approaches in TB drug development - To be confirmed

16:45 - 17:00 Discussion